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Haplotype-dependent allele-specific methylation (hap-ASM) can impact disease susceptibility, but maps of this phenomenon using
stringent criteria in disease-relevant tissues remain sparse. Here we apply array-based and Methyl-Seq approaches to multiple human
tissues and cell types, including brain, purified neurons and glia, T lymphocytes, and placenta, and identify 795 hap-ASM differentially
methylated regions (DMRs) and 3,082 strong methylation quantitative trait loci (mQTLs), most not previously reported. More than half
of these DMRs have cell type-restricted ASM, and among them are 188 hap-ASM DMRs and 933 mQTLs located near GWAS signals for
immune and neurological disorders. Targeted bis-seq confirmed hap-ASM in 12/13 loci tested, includingCCDC155, CD69, FRMD1, IRF1,
KBTBD11, and S100A*-ILF2, associated with immune phenotypes, MYT1L, PTPRN2, CMTM8 and CELF2, associated with neurological
disorders,NGFR andHLA-DRB6, associatedwith both immunological and brain disorders, and ZFP57, a trans-acting regulator of genomic
imprinting. Polymorphic CTCF and transcription factor (TF) binding sites were over-represented among hap-ASM DMRs and mQTLs,
and analysis of the human data, supplemented by cross-species comparisons to macaques, indicated that CTCF and TF binding likeli-
hood predicts the strength and direction of the allelic methylation asymmetry. These results show that hap-ASM is highly tissue specific;
an important trans-acting regulator of genomic imprinting is regulated by this phenomenon; and variation in CTCF and TF binding sites
is an underlyingmechanism, andmaps of hap-ASM andmQTLs reveal regulatory sequences underlying supra- and sub-threshold GWAS
peaks in immunological and neurological disorders.Introduction
Statistical evidence from genome-wide association studies
(GWASs) has implicated numerous DNA sequence vari-
ants, mostly SNPs, as candidates for inter-individual
phenotypic differences and disease susceptibility. How-
ever, most of these variants reside in non-coding regions,
and how they result in differences in phenotypes is not
well understood. Moreover, multiple statistical compari-
sons demand stringent thresholds for significance, p <
5 3 108 for a GWAS,1 and this level probably leads to
the rejection of many biological true positives with sub-
threshold p values. In fact, diseases interrogated with
well-powered GWASs demonstrate that the majority of
risk alleles have small effect sizes and would not achieve
genome-wide significance in more moderately sized co-
horts.2 Therefore, methods to provide biological validity
to both supra- and sub-threshold variants are a high prior-
ity. A combined genetic-epigenetic approach can help to
address this challenge. In particular, identification of
haplotype-dependent allele-specific methylation (hap-
ASM) in the human genome by our group (Kerkel et al.3)
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 2016 American Society of Human Genetics.lowed by others,6–15 led to suggestions that it might
contribute to inter-individual phenotypic variation and
that co-mapping this type of allelic asymmetry with
GWAS data could prove useful for promoting GWAS statis-
tical signals to biological true positives.16,17
ASM is a hallmark of two different phenomena: genomic
imprinting, where the methylation of an allele is deter-
mined by its parent-of-origin, and (non-imprinted) hap-
ASM, in which the local sequence context acts in cis to
dictate the methylation status of local CpGs.17 Hap-ASM
can be assessed either directly by bisulfite sequencing
(bis-seq) in heterozygotes or by methylation quantitative
trait loci (mQTL) analysis, which correlates net methyl-
ation of single CpGs with genotypes at nearby SNPs. Map-
ping hap-ASM and mQTLs and superimposing these maps
on GWAS data can support the biological relevance of
GWAS peaks, the hypothesis being that detection of hap-
ASM or an mQTL near a GWAS peak suggests the presence
of a bona fide regulatory SNP or haplotype, which reveals
its presence by conferring a physical asymmetry between
the two alleles in heterozygotes. Additional evidence,
including experiments in animal models, is needed for
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combined hap-ASM/mQTL/GWAS method, and related
methods such as eQTL/GWAS analysis,18 allows genome-
wide screening for regulatory loci, which can then be prior-
itized for such studies.
Understanding the mechanisms of hap-ASM could pro-
vide additional insights. Previously, we documented exam-
ples of genes with hap-ASM in which the differentially
methylated regions (DMRs) are discrete in size (1 to 2 kb)
and precisely overlap with binding sites for the insulator
protein CTCF,14 and we proposed a model for hap-ASM
in which polymorphisms in CTCF binding sites abrogate
CTCF binding in a haplotype-dependent manner and
lead to preferential CpG methylation of the unoccupied
allele.14,17 Here, we test this mechanism by genome-wide
and fine-mapping of CpG methylation patterns in human
tissues, supplemented by cross-species comparisons of
methylation patterns in Homo sapiens and macaques. In
parallel, we identify examples of strong hap-ASM DMRs
and mQTLs in T cells and brain, many of which are tissue
specific, not previously reported, and located near supra-
and sub-threshold GWAS peaks for immunological and
neurological diseases. Lastly, we find that an important
trans-acting regulator of genomic imprinting is in turn
regulated by hap-ASM.Material and Methods
Human and Macaque Tissues
The human tissues and cell types for this study are in Table S1.
CD3-positive T lymphocytes were isolated by negative selection
(RosetteSep, Sigma) from peripheral blood samples obtained
with informed consent. The GM12878 cell line DNA was pur-
chased from Coriell. All other human tissues were obtained from
autopsies. The mQTL discovery set included samples from 54 total
CD3-positive T cells, 44 temporal cortex (TC) gray matter samples,
18 NeuN-positive TC neurons isolated by FANS (see below), 22
non-neuronal brain cells (NeuN-negative from FANS; referred to
hereafter as glia), and 37 placenta samples (tissue taken from
immediately below the fetal surface and therefore not conta-
minated by maternal decidua). The hap-ASM discovery set for
Methyl-Seq, designed to represent a diverse human tissues,
included three T cell, three brain, two heart, two liver, one lung,
and two placenta samples. Informed consent was given for the
human samples and institutional review board (IRB) approval
obtained. The rhesus and bonnetmacaque (Macacamulatta and ra-
diata) tissues, including peripheral blood and liver, were obtained
from necropsies. The maintenance of the macaque colony was
approved by the Institutional Animal Care and Use Committee
of SUNY Downstate Medical Center.Isolation of Neuronal and Glial Nuclei by
Fluorescence-Activated Nuclear Sorting
Frozen tissue (0.25 to 0.5 g) was homogenized for 1 min on ice,
then layered over a 60% sucrose cushion and centrifuged at
28,500 rpm for 2.5 hr at 4 degrees, as described by Matevossian
and Akbarian.19 The pelleted nuclei were re-suspended and incu-
bated with anti-NeuN-Alexa 488 conjugated antibody (Millipore
cat# MAB377X; RRID: AB_2149209) for 1 hr at 4C prior toThe AmFANS. Both neuronal-enriched NeuN-positive and glial-enriched
NeuN-negative samples were recovered. Enrichment of NeuN-pos-
itive nuclei was confirmed by using an aliquot of the FANS samples
to prepare cytospin slides and visualized by fluorescence micro-
scopy. To assist nuclei visualization, the DNA was stained with
To-Pro3. Only samples that showed >95% Neu-N-positive cells
on analysis by NeuN immunofluorescence on cytospin slides
were utilized for DNA extraction. DNA was prepared from the
flow-sorted nuclei by standard SDS/proteinase-K lysis followed
by precipitation in 80% isopropanol with glycogen carrier.Illumina 450K Methylation Profiling and SNP
Genotyping for Identifying mQTLs
Genomic DNA (500 ng) was used as per the manufacturer’s in-
structions for HumanMethylation450 Beadchips (Illumina), with
all assays performed at the Roswell Park Cancer Institute (RPCI)
Genomics Shared Resource. Data were processed with Genome
Studio, which calculates the fractional methylation (AVG_Beta)
at each queried CpG, after background correction, normalization
to internal control probes, and quantile normalization. All probes
mapping to the X or Y chromosome were removed, along with
probes that queried CpGs overlapping the positions of known
common DNA variants as reported in dbSNP build 138 (allele fre-
quencyR 1%), because these CpGs are destroyed by the SNP itself.
As recommended by Illumina, AVG_Beta values with a detection
p value > 0.05 were excluded from the analysis and replaced by
missing values. A small number of probes (<0.06%) with more
than 20% missing values were excluded. In parallel, the DNA
samples were genotyped on Illumina HumanOmni2.5 Beadchips,
followed by initial data processing with Genome Studio. SNPs
were annotated with dbSNP138.
We mapped mQTLs in each tissue and cell type using combined
SNP genotyping and 450K methylation data. Only SNPs with at
least three samples per genotype (AA, AB, and BB, where A is the
reference and B the alternate allele), with frequencies in Hardy-
Weinberg equilibrium, were analyzed. Exact tests of Hardy-Wein-
berg equilibrium for two allele markers were performed with R
‘‘genetics’’ package and SNP genotypes with a p value < 0.05
were considered in disequilibrium and excluded from further
analyses. Previous studies have found that methylation at mQTLs
correlates best with nearby SNPs, with the correlations decaying
rapidly over 1–2 kb and the majority of mQTLs located within
100 kb.8,12,15 Because our data confirmed this finding, we focused
on CpGs located within 75 kb on either side of heterozygous SNPs
(150 kb windows) to assess SNP-CpG methylation correlations.
The SNPs and CpGs meeting these criteria are referred to hereafter
as index SNPs and informative CpGs. For mQTLs, we required that
the fractional methylation of a given CpG should be a linear func-
tion of the genotype of the index SNP, where a numeric value has
been assigned to each genotype as follows: AA ¼ 0, AB ¼ 1, and
BB¼ 2. The coefficient b of the function reflects the additive effect
of one alternative allele, such that 2b is the methylation difference
between allele A and B. Thus, we searched for mQTLs using linear
regression to model the relationship between the fractional
methylation (AVG_Beta) and index SNP genotype. Each index
SNP-CpG pair within the 150 kb window was tested. We defined
mQTLs as CpGs with an R-squaredR 0.5 (which reflects the good-
ness of the fit to the linear function), a coefficient bR 0.1, and p
value corrected for multiple testing using Benjamini-Hochberg
method< 0.05 (FDR at 5%). The importance of using each of these
criteria is explained further in Figure S1. We ranked the mQTLs byerican Journal of Human Genetics 98, 934–955, May 5, 2016 935
strength of allelic asymmetry using the geometric mean of the dif-
ference in fractional methylation between the A and B alleles, and
the R-squared value. Potential batch effects in the 450K data were
assessed by multivariate linear regression including the batch and
genotype as explanatory covariates. Minimal batch effects were
observed, such that 94% of the mQTLs remained significant after
batch correction. For testing mechanistic hypotheses by enrich-
ment analyses, to avoid bias due to multiple mQTL CpGs within
a small window, and to parallel our deep bis-seq data where the
average DNA fragment length was 250 bp, consecutive mQTL
CpGs within 250 bp were considered as a single DMR.
In the data from the brain samples, half of which were neuropa-
thologically normal and the other half affected by late-onset Alz-
heimer disease (AD [MIM: 104300]), we ruled out the effect of
AD status on the identified mQTLs by performing multivariate
linear regression, including the genotype, the disease status, and
the interaction term between disease status and genotype as
explanatory covariates. The coefficient b of the disease reflects
the overall effect of AD on net methylation, and the coefficient
b of the interaction term reflects the effect of AD on the correlation
betweenmethylation and genotype. Thus, a significant coefficient
b of the disease suggests a methylation difference between AD
versus control samples, and a significant coefficient b of the inter-
action term suggests that mQTL presence or strength is different
between AD and controls. All analyses were performed with R.Agilent SureSelect Methyl-Seq for Mapping ASM
We used the Agilent SureSelect Methyl-Seq DNA hybrid capture
kit, followed by Nextgen bis-seq. In this protocol, targeted regions
(total of 3.7M CpGs) include RefGenes, promoter regions, CpG
islands, CpG island shores, shelves, and DNase I hypersensitive
sites. DNA was sheared to an average size of 250 bp and bisulfite
converted with the EZ DNA methylation kit (Zymo). Paired-end
reads (150 bp) were generated with an Illumina HiSeq2000
sequencer. One of the brain samples was relatively under-repre-
sented in the library, so additional sequences were generated on
a MiSeq sequencer to improve the coverage for this sample. After
trimming for low-quality bases (Phred score < 30) and reads
with a length < 40 bp with TrimGalore, the reads were aligned
to the human genome (GRCh37) using Bismark20 and duplicate
reads were removed with Samtools. Coverage metrics were calcu-
lated with Picard tools and SNP calling was performed with
BisSNP.21 Genotyping was carried out with human genome
GRCh37 and dbSNP137 as references. We filtered out heterozy-
gous SNPs with fewer than ten reads per allele. Bisulfite treatment
converts unmethylated C residues to T, whereas methylated C res-
idues are not converted. Therefore, for C/T and G/A SNPs (depend-
ing on the strand), the distinction between the alternate allele and
bisulfite conversion is not possible and these SNPs are not infor-
mative for hap-ASM analysis. However, because Agilent SureSelect
captures negative stranded DNA fragments, only G/A SNPs needed
to be filtered out. ASM calling was performed with Bismark, after
separating the valid SNP-containing reads by allele. Informative
SNPs were defined as non-G/A heterozygous SNPs that passed
BisSNP criteria and were covered by more than ten reads per allele.
Informative regions were defined as regions with overlapping
reads covering at least one informative SNP. To further increase
the stringency and accuracy of ASM calling, only regions with at
least three CpGs covered by more than ten reads per allele were
considered. ASM CpGs were then defined as CpGs with Fisher’s
exact test p value< 0.05. Hap-ASM regions were defined as regions936 The American Journal of Human Genetics 98, 934–955, May 5, 2with R20% methylation difference after averaging all CpGs
covered, and a Wilcoxon p value corrected for multiple testing
by Benjamin-Hochberg method < 0.05 (FDR at 5%). We ranked
the ASM regions by allelic asymmetry using the geometric mean
of the methylation difference, number of ASMCpGs, and percent-
age of ASM CpGs among all covered CpGs. Data post-processing
was performed by R. Although this study focuses on hap-ASM,
genomic imprinting also produces ASM, affecting approximately
100 DMRs. Therefore, we used the GeneImprint database to flag
all known imprinted chromosomal domains, which additionally
served as positive internal controls for ASM detection in our exper-
iment. ASM regions within 575 kb of the transcription starting
site of known imprinted genes were not considered as hap-ASM
and are listed separately in Table S5.
Validations and Fine-Mapping of Hap-ASM DMRs via
Targeted Bis-Seq
Targeted bis-seq was utilized for validation and fine-mapping of
hap-ASM and mQTL regions. Primers (Table S2) were designed in
MethPrimer, and bisulfite-converted DNA was amplified by
PCR, followed by either Sanger or Nextgen (Illumina MiSeq)
sequencing. Sample preparation for MiSeq was performed on a
Fluidigm AccessArray high-throughput PCR machine with sample
bar-codes incorporated in a second round of PCR, as described.14
PCRs for Sanger and MiSeq were performed in triplicate and
pooled to ensure sequence complexity. For Sanger sequencing,
PCR products were cloned using the TopoTA Cloning System (In-
vitrogen) as described.22 ASM was assessed when the coverage was
at least 10 clones per allele for Sanger sequencing and 100 DNA
fragments for MiSeq sequencing. Although the absolute differ-
ences between methylation of the two alleles are not exaggerated
by very deep sequencing, the p values tend to zero as the number
of reads increases. Therefore, to allow comparisons with the
Sanger sequencing data, for the MiSeq data we carried out boot-
strapping (1,000 random samplings, 20 reads per allele). Signifi-
cance of methylation differences between alleles was assessed via
the Wilcoxon test. Samplings and bootstrapping were performed
with R. For graphical representations of the MiSeq data, one repre-
sentative sample is shown.
Bis-Seq Analysis of 5mC and 5hmC
To assess the relative contributions of 5mC and 5hmC to ASM, we
used the TrueMethyl 6 kit (CEGX), according to the instructions of
the manufacturer. This chemical conversion-based approach uses
bis-seq of multiple clones to separately score 5mC-only, so that
the percent contribution of 5hmC to net methylation at each
CpG can be inferred from the difference of net methylation
observed using oxy-bis-seq and traditional bis-seq. For this pur-
pose, we required at least 12 clones per allele for both oxy-bis-
seq and traditional bis-seq.
Annotation of Hap-ASM and mQTL Regions and
Bioinformatic Enrichment Analysis
To annotate hap-ASM loci and mQTLs, we defined small (200 bp,
500 bp) and large (150 kb) windows centered on each informative
region for the hap-ASM DMRs and centered on each informative
CpG for the mQTLs. The small windows were used to assess
mechanistic hypotheses involving local sequence elements and
chromatin states, and the large windows were used as an approx-
imation of haplotype blocks for assessing proximity of hap-ASM
DMRs and mQTLs to GWAS peaks. From the UCSC Genome016
Browser (GRCh37 assembly), we downloaded RefSeq annotations,
CpG islands, conserved elements, repetitive elements, and CTCF
and TF peaks and motif occurrences in all cell lines from ENCODE
and related projects (GEO: GSE29611, GSE27584, GSE30263,
GSE31477).23,24 Chromatin states in lung, heart, liver, placenta,
T cell, brain, astrocyte, and H9-neurons were downloaded from
the Roadmap Epigenomics project (GEO: GSE18927). We aggre-
gated the 70 cell lines queried for CTCF binding peaks into 17
cell types (Table S3) and classified CTCF peaks by strength accord-
ing to the 25th, 50th, and 75th percentile of all peak values. Cell
restricted, multi-cell, and pan-cell peaks were defined with the
25th, 50th, and 75th percentile of the number of cell types. For
analyzing CTCF binding site motifs, we scored occurrences of
the canonical sequence identified by ENCODE, as well as de
novo predicted motifs identified by Kheradpour and Kellis.23
GWAS traits and associated SNPs were downloaded from NHGRI.
We used BedTools to intersect the genomic coordinates of our
informative and hap-ASM/mQTL regions to the coordinates of
the annotation sets, using 150 kb windows for GWAS traits/SNPs
and gene name annotations and 200 bp and 500 bp windows
for annotations of local sequences and chromatin features.
To test whether hap-ASM occurs at specific types of sequences
more often than random expectation, we used univariate logistic
regression with hap-ASM or mQTL as the dependent variable
and the tested sequence feature as the explanatory covariate.
Because hap-ASM regions have different sizes, to avoid bias due
to a higher probability of longer regions to overlap with regulatory
elements, enrichment analysis was carried out with fixed win-
dows. To test for robustness, we ran each analysis with two
different window sizes, 200 bp and 500 bp, centered on each
DMR. Because the denominator for the enrichment analyses de-
pends on the platform, we performed all enrichment analyses
separately for hap-ASM DMRs and mQTLs. To test the effect of
ASM CpG density, hap-ASM regions were categorized as three
levels, with 3, 4–5, and >6 ASM CpGs. The tested regulatory
element was defined as the dependent variable and hap-ASM, cate-
gorized according to the number of hap-ASM CpGs, was the
explanatory covariate. Multivariate logistic regression was used
to adjust for the number of CpGs, so that CpG-rich hap-ASM re-
gions would not be compared to CpG poor regions. For enrich-
ment analysis of polymorphic CTCF binding sites and TF binding
sites (TFBS) among hap-ASM regions, polymorphic sites were
defined as motif occurrences in a 200 bp window containing at
least one informative SNP. For the 500 bp window and mQTLs,
polymorphic binding sites was defined as motif occurrences con-
taining at least one SNP with minor allele frequency R 0.2,
because based on our sample size, rarer SNPs were unlikely to be
sufficiently informative. The effect of polymorphisms on CTCF
and TF binding likelihood was estimated for each allele by their
position weight matrix (PWM) score:
X
i;j
pi;jlog

pi;j
.
pb

:
Here pi,j is the probability of the nucleotide for each position in
the PWM from the ENCODE data, and pb the nucleotide back-
ground frequency assuming equal probabilities of each nucleotide
(pb ¼ 0.25). For motif occurrences with a PWM score > 3, correla-
tions between allelic difference of methylation and difference of
PWM score were assessed via linear regression.
To assess DMR boundaries, we used our T cell mQTL dataset.
Because estimation of the boundaries is limited by 450K CpG
coverage, we looked for mQTL CpGs in CpG-rich regions, withThe Amat least one CpG in the proximate 500 bp, one CpG between
500 bp and 1,000 bp, one CpG between 1,000 bp and 2,000 bp,
and one CpG after 2,000 bp, upstream and downstream of the in-
dex CpG. The boundaries of mQTLs were defined as at least two
consecutive CpGs whose methylation lacked significant correla-
tion with the index SNP. Fine mapping of hap-ASM DMRs directly
via the Agilent Methyl-Seq data was performed on seven hap-ASM
regions for which the 2 kb upstream and downstream flanking re-
gions contained at least one heterozygous SNP in samples with
hap-ASM. For eQTL enrichment analysis, genes in 150 kbwindows
spanning ASM DMRs and mQTLs were annotated with the eQTL
browser. The distance to eQTLs was defined as the distance to
the transcriptional start site of the genes showing eQTLs. Analyses
were performed with R and STATA statistical software.Results
Methyl-Seq in Multiple Primary Human Tissues
Produces Maps of Hap-ASM
The terms mQTL and hap-ASM are related, but not synon-
ymous. Although they both describe the same class of
allelic asymmetry, in which the DNA methylation on
each allele is sequence dependent, they are mapped by
different strategies (Material and Methods and Figure S1).
To test pan-tissue mechanisms and identify ASM DMRs
near statistical peaks from diverse GWA studies, our
Methyl-Seq sample set included diverse human tissues,
including brain, T cells, placenta, liver, heart, and lung
from different individuals (Table S1). In contrast, our
array-based approach for mapping mQTLs utilized larger
numbers of samples, concentrating on T cells, brain, and,
in a smaller set, placentas. In total, the two approaches pro-
vided information on 3.7 million CpGs in the Methyl-Seq
data to directly identify ASM, and 485,000 CpGs in the
array-basedmethylation data, whichwe used with Illumina
2.5M SNP array data to identify mQTLs.
By Methyl-Seq, we obtained a median fragment length
of 200 bp and mean depth of coverage in the targeted re-
gions ranging from 50 to 94 across the samples, with
80% of these regions covered by more than 20 reads
(Figure S2). We were able to query 278,897 CpGs located
in the same fragments as 44,851 index SNPs. Among
them, 42,904 CpGs (15%) showed significant asymmetry
of fractional methylation between the two alleles by
Fisher’s exact test at p < 0.05. Asymmetric methylation re-
sulting from the loss of CpG sites due to the presence of
SNPs accounted for 30% of these CpGs (12,856 CpGs).
Such sites can be interesting for gene regulation, but for
our subsequent analyses we did not consider these geneti-
cally polymorphic CpGs as having ASM. Thus, from this
experiment we brought forward 30,048 CpGs with bona
fide ASM for bioinformatic enrichment analyses.
Because analyzing epigenomic data both at the level of
the individual CpG and the differentially methylated re-
gion (DMR) improves specificity and is crucial for testing
mechanisms,25 we used both approaches. To identify
strong ASM DMRs, ASM regions were defined by at leasterican Journal of Human Genetics 98, 934–955, May 5, 2016 937
three CpGs with significant allelic asymmetry in fractional
methylation (Fisher’s exact test p < 0.05). We further
required at least two contiguous CpGs with ASM, and an
absolute difference in fractional methylation ofR20% be-
tween alleles after averaging over all covered CpGs in the
DMR. The significance threshold for the difference in frac-
tional methylation between alleles was set at a Wilcoxon
test p value with multiple testing correction < 0.05 (FDR
at 5%). With these cut-offs, we found 795 strong
hap-ASM regions, representing 2% of all informative
SNP-containing regions (Figure S2 and Table S4). Some of
the hap-ASM DMRs overlapped with promoter sequences
near transcriptional start sites, but most were intergenic
or intronic, with a modest enrichment in intergenic re-
gions (OR ¼ 1.3, p ¼ 0.001). CpG islands were represented
among the hap-ASM DMRs but were not found to be en-
riched (Figure S3). Interestingly from an evolutionary
perspective, conserved sequence elements were signi-
ficantly under-represented among hap-ASM DMRs
compared to polymorphic regions without hap-ASM
(OR ¼ 0.74, p ¼ 9 3 105).
In the above analyses we deliberately excluded all CpG-
containing reads thatmapped toknown imprintedchromo-
somal domains. However, we identified other clusters of
reads with ASM mapping within 150 kb windows centered
on 47 known imprinted genes (Table S5). This finding of
multiple imprinted loci, representing a 5-fold increase over
random expectation (p¼ 63 1029), serves as a positive in-
ternal control for our overall experiment. As supported by
our targeted bis-seq in series of heterozygous individuals
(below), the large majority of ASM loci revealed by the
Methyl-Seq data in fact represent hap-ASM, not imprinting.
Identification and Mapping of Hap-ASM in ZFP57,
a trans-Regulator of Genomic Imprinting
Hap-ASM in a gene with interesting biological functions
can provide a concrete example of our Methyl-Seq and
mQTL findings. We used targeted bis-seq to fine-map a
hap-ASM DMR and mQTL that our data had revealed
3.5 kb upstream the transcription start site of ZFP57
(MIM: 612192) on chromosome 6 (Figure 1 and Table 1).
This gene, in the KRAB domain-containing ZNF superfam-
ily, is not imprinted (confirmed by binomial test in our
series of heterozygotes), but it codes for a TF that is an
important trans-acting regulator of DNA methylation im-
prints.26,27 The bis-seq data from a contig of 12 amplicons,
each covering a high frequency (i.e., informative) SNP and
at least three CpGs, showed that hap-ASM in this region
spans a discrete DMR of 2 kb, with allelic asymmetry in
6/6 T cell samples tested (Figure 1). This DMR is located
between a GWAS SNP associated at sub-threshold sig-
nificance with migraine (MGR1 [MIM: 157300]; p ¼
9 3 106) and another with multiple sclerosis (MS
[MIM:126200]; at supra-threshold significance, p ¼ 1017).
Additional validations of hap-ASM in T cells and brain
samples are in Figure 2, and our mapping of the hap-
ASM region in brain revealed the same DMR as in T cells938 The American Journal of Human Genetics 98, 934–955, May 5, 2(Figure S4). Of mechanistic importance (see below), these
data show that the ZFP57 hap-ASM DMR precisely over-
laps an ENCODE CTCF binding peak (Figures 1 and S4).
To further assess tissue specificity, we carried out targeted
Nextgen bis-seq in a wider range of tissues from multiple
individuals and found that hap-ASM is strong in T cells
and brain, weaker in colon, heart, liver, lung, and mono-
cytes, and absent in placenta, where the DMR is bialleli-
cally hypomethylated (Figure S4).
Pan-tissue and Tissue-Specific mQTLs in
T Lymphocytes, Brain, and Placenta
We next assessed cis-regulated mQTLs in T cells, brain tem-
poral cortex (TC) graymatter, FANS-isolated NeuN-positive
TC neurons, FANS-isolated non-neuronal TC cells (NeuN-
negative; hereafter referred to as glia, but understood to
include other cell types such as microglia), and placenta.
Overall, 138 samples were included in this discovery phase
(Table S1). Because previous reports have shown that CpG
methylationatmQTLs correlatesmost stronglywithnearby
SNPs,8 we restricted our analyses to CpGs in 150 kb win-
dows centered on each index SNP. This window size is in
fact sufficient to capturemost cis-regulatedmQTLs, as indi-
cated by the decay curve of the correlation coefficients in
our data (Figure S5). Overall, 451,419 CpGs were informa-
tive in T cells, 450,805 in brain TC, 444,047 in neurons,
447,867 in glia, and 450,631 in placenta. Using linear
regression corrected for multiple testing, we assessed corre-
lations between genotypes andmethylation for each index
SNP-CpG pair, defining anmQTL by p value and effect size,
namely a significant linear correlation (p value corrected for
multiple testing < 0.05), R-squared R 0.5, reflecting the
goodness of fit to the linear model, and a regression b coef-
ficient associated with genotypeR 0.1, corresponding to a
difference in net methylation between the two alleles R
0.2. The importance of combining statistical significance
and effect size criteria is highlighted by the examples in
Figure S1. Using these criteria, we identified 1,440 mQTL
CpGs in Tcells, 737 in unfractionated brain TC, 364 in neu-
rons, 867 in glia, and 866 in placenta (Figure S2 and Tables
S6–S10). Like the hap-ASM loci, the mQTLs were enriched
in intergenic CpGs (OR ¼ 1.9, p ¼ 2.1 3 1063), with pro-
moter CpGs being present but relatively under-represented
(OR ¼ 0.68, p ¼ 5.5 3 1021; Figure S3).
We found marked tissue specificity among the sets of
mQTLs (Figures 1, 2, and S6). As expected, most of the
mQTLs in unfractionated brain TCwere also found in puri-
fied neurons or glia (61%), but only 28% ofmQTLs in brain
tissue and purified brain cells overlapped with mQTLs in
T cells, and 12% with mQTLs in the placentas. To further
assess cell type specificity, we superimposed informative
CpGs in neurons and glia and identified 188 neuron-
restricted (or neuron-stronger) and 602 glia-restricted
(glia-stronger) mQTL CpGs (Figure 2). Because most of our
neuron and glia preparations were paired samples from
the same brains, we were able to perform a sub-analysis
including only the paired samples, which confirmed the016
Figure 1. Hap-ASM DMRs and mQTLs in
the HLA Region on Chromosome 6, and
Targeted Bis-Seq Defining a Hap-ASM
DMR Upstream of ZFP57
(A) Map of hap-ASM and mQTLs on
chromosome band 6p22.1. The tracks
show log10 q values for hap-ASM DMRs
in the overall Methyl-Seq dataset and for
mQTLs in each of the indicated tissues.
Although there are some pan-tissuemQTLs,
most are tissue specific. As explained in the
text, the net yield of loci from the hap-
ASM and mQTL approaches is additive.
(B) Zoomed-in view of ZFP57, showing
relevant ENCODE tracks and the ampli-
cons utilized for targeted bis-seq.
(C) Results of targeted bis-seq showing that
the ZFP57 hap-ASM DMR spans approxi-
mately 2 kb in T cells. The major DMR
(amplicons in the gray rectangle) precisely
overlaps a strong CTCF ChIP-seq peak and
is located between two GWAS SNPs, one
associated with migraine (p ¼ 9 3 106)
and the other with multiple sclerosis
(p ¼ 1017). A weaker DMR is found over-
lapping a second CTCF peak (amplicon
11). Circles represent consecutive CpGs,
with each line being a unique read. White
circles are unmethylated CpGs and black
circles are methylated CpGs. Alleles 1 and
2 represent the methylated and unmethy-
lated alleles in these heterozygous samples.
Wilcoxon p values and methylation differ-
ences were calculated by bootstrapping
(1,000 sampling of 20 reads per allele)
and are indicated only for significant
hap-ASM (D fractional methylation >
0.2, >3 ASM CpGs, and p < 0.05). One
representative random sample of each
allele (20 reads per allele) is shown. Valida-
tions and fine-mapping of this DMR
in other tissues and cell types are in Fig-
ures 2 and S4. D, absolute difference in
percentage of methylation between alleles
in heterozygous samples; q value, p value
corrected for multiple testing using the
Benjamini-Hochberg method; values are
from bootstrapping.cell type specificity (Figure S6). This situation is illustrated
by our targeted bis-seq data for a GWAS peak-associated
hap-ASM region upstream of NGFR (MIM: 162010), coding
for the NGF receptor that binds neurotrophins.28 The re-
sults confirmed ASM that is strong in neurons, moderately
strong in T cells, and weak or absent in glial cells and
placenta (Figure S7). As we show below, allele-specific TF
binding site occupancy is one mechanism of hap-ASM
andmQTLs, and it can partly explain this tissue specificity.
However, differences in global methylation levels between
tissues probably also play a role. Such differences are
revealed in our data by comparing the mean CpG methyl-
ation levels genome-wide in T cells, brain, and placenta,
expressed as Kernel density plots in Figure S2, which show
that the most divergent tissue for mQTLs and hap-ASM,
the placenta, has global CpG hypomethylation compared
to the other two tissues.The AmAs an important technical and biological point, among
the 44 adult TC gray matter samples in this experiment,
22 were without significant neuropathological changes
and 22 showed neuropathological findings of moderate
to severe late-onset AD. To test for possible AD-specific ef-
fects on DNA methylation in the brain mQTLs, we carried
out multivariate linear regression including the genotype,
the disease status, and the interaction term between
disease status and genotype. This procedure revealed no
significant AD-specific effects on DNA methylation at the
mQTL CpGs, and no differential genotype effects on
methylation levels in AD compared to controls (Tables
S7–S9). This finding of little influence of AD neuropa-
thology on DNA methylation patterns is consistent with
the low yield of differentially methylated loci in prior
case-control studies,29–32 particularly those passing a
p value corrected for multiple testing < .05 and fractionalerican Journal of Human Genetics 98, 934–955, May 5, 2016 939
Table 1. Examples of Disease-Relevant Loci with Hap-ASM or mQTLs
Primary
Dataset and
Ranking for
Strength of
Hap-ASM
or mQTL
SNP in Phase
with Hap-ASM
or mQTLa
Closest Genes
in 150 kb
Window
Targeted
Bis-Seq
Validationsb
GWAS Signals in 150 kb Window
Centered on Hap-ASM DMR or mQTL
Immune System
hap-ASM (15);
mQTL (33)
chr1: rs9330298;
cg08477332
S100A*,
SNAPIN, ILF2
brain: 7/8;
T cell: 7/7
rs7536700; myeloma;
p ¼ 4.00 3 106
– –
hap-ASM (107);
mQTL (302)
chr5: rs2549004;
cg21138405
IRF1, IL5, RAD50 brain: 1/7;
T cell: 9/12
rs11745587; asthma;
p ¼ 2.00 3 106
rs12521868; CD;
p ¼ 1.00 3 1020
rs2188962; IBD;
p ¼ 1.00 3 1052
hap-ASM (179) chr6: rs1565443;
haplotype:
rs1565441;
rs1565442;
rs1565443;
rs6937877;
rs9364402
FRMD1 brain: 0/10;
T cell: 7/15;
T cell: 7/7
rs1473500 ; Immune
resp.; p ¼ 3.00 3 107
– –
hap-ASM (183) chr12:
rs12304510
CLECL1, CD69,
CLEC2D
brain: 0/7;
T cell: 5/9
rs10466829; MS;
p ¼ 1.00 3 108
rs4763879; T1D;
p ¼ 2.00 3 1011
rs11052552; T1D;
p ¼ 7.00 3 107
hap-ASM (45) chr19:
rs10411630
CCDC155,
DKKL1, TEAD2
brain: 5/8;
T cell: 2/3
rs2303759; MS;
p ¼ 5.00 3 109
– –
hap-ASM (137) chr19:
rs12975442
EVI5L, MAP2K7,
TGFBR3L
GM12878; LBCL rs558718;
HIV-1 control;
p ¼ 4.00 3 106
– –
Immune System and Brain
hap-ASM (61);
mQTLc (23)
chr6:
rs78274956;
cg05844871
HLA-DRB6 brain: 9/9;
T cell: 1/6
rs4530903; SCZD;
p ¼ 5.00 3 106
rs9271192; AD;
p ¼ 3.00 3 1012
rs3828840; MS;
p ¼ 5.00 3 1015
hap-ASM (16);
mQTL (279)
chr6: rs2747429;
cg16885113
ZFP57, MOG,
HLA-F
brain: 4/4;
T cell: 5/5
rs3095267; migraine;
p ¼ 9.00 3 106
rs2523393; MS;
p ¼ 1.00 3 1017
rs9258260; CD;
p ¼ 2.00 3 1010
mQTL (58) chr17:
rs2412102;
cg10163794
PHB, NGFR neur: 4/4;
glia: 0/2;
T cell: 4/4
rs16948200 ;
immune resp.;
p ¼ 2.00 3 108
rs1035050; bipolar;
p ¼ 9.00 3 106
–
Brain
hap-ASM (440) chr2:
rs11684605
PXDN, MYT1L brain: 4/8;
T cell: 0/8
rs6735179;
antipsychotic Rx;
p ¼ 1.00 3 107
– –
hap-ASM (65) chr3: rs9838223 CMTM8, GPD1L brain: 7/11;
T cell: 0/5
rs9825310; alcohol
dep.; p ¼ 8.00 3 106
rs4380451; bipolar;
p ¼ 4.00 3 106
–
hap-ASM (527) chr7:
rs35487364
PTPRN2 brain: 2/12;
T cell: 0/6
rs6459804;
bipolar, SCZD;
p ¼ 8.00 3 106
– –
mQTL (116) chr22:
rs7893689;
cg04065885
CELF2 glia: 6/6 rs201119; AD;
p ¼ 1.00 3 108d
rs2242451; AD;
p ¼ 0.003d
–
To test the validity of our criteria for calling hap-ASM and mQTLs, we deliberately chose loci in a wide range of strength of allelic asymmetry (rankings) and with at
least one nearby GWAS signal associated with a disease-relevant tissue or cell type. The results of bis-seq (numbers of heterozygotes with allelic asymmetry in
methylation of total numbers of heterozygotes) highlight tissue specificity of the hap-ASM. In addition, two of these regions showed inter-individual differences
in the presence or absence of hap-ASM. For one of them, the FRMD1 region, we showed that extended haplotypes rather than the index SNP alone dictate methyl-
ation asymmetry (Figure S11). Many of these loci are in genomic regions with sub-threshold GWAS signals, and in these situations, the epigenetic data provide
independent evidence for biological significance. GWA datawere obtained from theNHGRI-EBI GWASCatalog. References for GWAS are listed in the Supplemental
Data, as well as additional references for candidate genes. Abbreviations and OMIM numbers are as follows: AD, Alzheimer’s disease; Alcohol dep., alcohol depen-
dence; antipsychotic Rx, response to antipsychotic therapy (MIM:NA); bipolar, bipolar affective; CD, Crohn disease; HIV-1 (HIV-1, susceptibility to [MIM: 609423]);
Immune response, immune response to smallpox (MIM: NA); IBD, inflammatory bowel disease (IBD1 [MIM: 266600)]); MS, multiple sclerosis; Myeloma, multiple
myeloma; SLE, systemic lupus erythematosus (SLE [MIM: 152700]); SCZD, schizophrenia; T1D, type I diabetes mellitus; ALG12 (MIM: 607144), ARC (MIM:
604223), ARL11 (MIM: 609351), BRD1 (MIM: 604589), DKKL1 (MIM: 605418), EBPL (MIM: NA), EVI5L (MIM: NA), GPD1L (MIM: 611778), HLA-F (MIM:
143110), IL5 (MIM: 147850), JRK (MIM: 603210), MAP2K7 (MIM: 603014), MOG (MIM: 159465), PHB (MIM: 176705), PSCA (MIM: 602470), RAD50
(MIM: 604040), RCBTB1 (MIM: 607867), SNAPIN (MIM: 607007), TEAD2 (MIM: 601729), TGFBR3L (MIM: NA), ZBED4 (MIM: 612552), NA, not available.
aHighest ranking index SNPs and CpGs are listed here; see Tables S4 and S6–S10 for complete lists and SNPs in phase with mQTLs.
bHeterozygotes assessed by Agilent Methyl-Seq and/or targeted bis-seq.
cThe 150 kb window centered on this validated DMR contains 29 additional mQTLs in brain including cg20532376, cg00119778, cg13972202, cg10466124,
cg18111114, cg00103771, cg07984380, cg13910785, cg19575208, cg08845336, and cg00598125 (Table S7).
dAD-associated SNPs were reported in Lee et al.67 and Wijsman et al.68
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Figure 2. Genome-wide Data and Tar-
geted Bis-seq Highlight Pan-tissue and
Tissue-Restricted Hap-ASM
(A) Venn diagrams of mQTLs identified in
placenta, brain, T cells, neuron, and glia,
showing that although pan-tissue mQTLs
can be found, the majority of mQTLs are
tissue or cell type specific. Only mQTLs
withCpGs-SNP pairs that were informative
in every tissue are considered here. Thus,
the numbers in these diagrams are some-
what smaller than the total mQTLs listed
in the Tables S6–S10.
(B) Validation of hap-ASM regions identi-
fied in the S100A** cluster, ZFP57,
CCDC155, FRMD1, CLECL1, PXDN, and
HLA-DRB**. Whereas hap-ASM in the
S100A** cluster, ZFP57, and CCDC155 is
robust in both T cells and brain, the hap-
ASM DMRs in FRMD1 and CLECL1 are
strong in T cells but weak or absent in
brain. Conversely, hap-ASM in PXDN and
HLA-DRB6 is significant in brain but not
or only weakly in T cells. Alleles A and B
represent, respectively, the reference and
alternative allele of one heterozygous sam-
ple. The p values were calculated as in
Figure 1. Table 1 lists the number of hetero-
zygous samples subjected to bis-seq.
Figures 3, 4, and S10–S17 show bis-seq val-
idations in additional samples and loci.methylation difference R 0.1, which corresponds to the
sensitivity of Illumina Beadchip arrays.33,34 The AD-associ-
ated CpGs from the largest of those studies30–32 showed no
significant differences inmethylation between the AD case
and control subjects in our dataset (differences in mean
fractional methylation ranging from 0.00003 to 0.06,
with 95% less than 0.03, consistent with Lunnon et al.,31
and none passing FDR at 0.5; Table S12). Nonetheless, as
we discuss below, our mQTL and hap-ASM data from brain
cells are in fact useful as an adjunct to GWAS data for
mapping genes and regulatory sequences that underlie in-
ter-individual differences in AD susceptibility.
ASM and mQTL Screens Are Complementary
Approaches
When we compared the informative regions between our
mQTL and Methyl-Seq datasets, we found little overlap,
with only 4.5% of the informative 450K CpGs queried byThe American Journal of HumaMethyl-Seq and, conversely, 40% of
the informative Methyl-Seq regions
covering at least one informative
450KCpG.Only 2%of the array-infor-
mative CpGs and 16% of Methyl-Seq-
informative regions were assessed by
the same informative SNPs in both
approaches Thus, as shown for one
chromosomal region in Figure 1A
and summarized globally in Figure S2,
combining the two methods gives anadditive yield, allowing a more comprehensive profiling of
hap-ASM, and its surrogate mQTLs, through the genome.
Hap-ASM and mQTLs Highlight Regulatory Regions
near Supra- and Sub-threshold GWAS Peaks Associated
with Immunological and Neurological Disorders
Overlapping our datawith theGWAS catalog,we found397
strong hap-ASM regions from our multi-tissue experiment
and 778 T cell, 395 brain (unfractionated TC), 204 neuron,
483 glia, and 474 placenta mQTLs with at least one GWAS
SNP in a 150 kb window centered on the mQTL or hap-
ASM DMR. These loci are listed and ranked by strength of
allelic methylation asymmetry in Tables S4 and S6–S10.
To focus on the loci of greatest interest, we next narrowed
our search to GWA traits relevant to the tissue or cell type
in which we had identified the hap-ASM or mQTL. This
procedure revealed 61 hap-ASM DMRs and 257 T cell,
148 brain, 81 neuron, and 179 glia mQTLs located withinn Genetics 98, 934–955, May 5, 2016 941
Figure 3. Fine-Mapping of Hap-ASM in
the S100A*-ILF2 Region, Containing a
Sub-threshold GWAS Signal for Multiple
Myeloma, Reveals DMRs Overlapping
with CTCF Binding Sites
The map and genome browser tracks show
a strong hap-ASM DMR identified by both
Methyl-Seq and mQTL analysis. The DMR
is validated by targeted bis-seq in an inter-
genic region of the S100A* gene cluster,
located 70 kb from a subthreshold GWAS
peak (p ¼ 43 106) for multiple myeloma.
The DMR (solid rectangle) overlaps exactly
with a CTCF ChIP-seq peak, with the index
SNP located in the CTCF binding motif.
A second weaker hap-ASM region identi-
fied by the fine-mapping in T cells and by
mQTL analysis, overlaps another CTCF
peak (dashed rectangle). Amplicon 9 con-
tains a SNP CpG eliminating the CpG on
the hypomethylated allele. Nextgen bis-
seq (MiSEQ) was performed for all ampli-
cons, except amplicons 8 and 10 (*, Sanger
sequencing). For the MiSEQ data, the
p values were calculated as in Figure 1.
For Sanger sequencing, we required at least
ten clones per allele.75 kbof tissue-relevantGWASpeaks (Tables S4 and S6–S10).
Hap-ASM loci were often located near GWAS peaks, but
were not specifically enriched for such locations. However,
the combined larger sets of brain and T cell mQTLs were
moderately but significantly enriched within 150 kb win-
dows centered on GWAS peaks (OR ¼ 1.3, p ¼ 1.8 3 109).
Targeted Bis-Seq of Hap-ASM and mQTL Regions
Validates the Genome-wide Data, Localizes DMR
Boundaries, and Reveals Inter-individual Variability
We next selected additional genes for validations and fine-
mapping of their DMRs using Nextgen and Sanger bis-seq.
As shown in Table 1, these loci included six hap-ASM
DMRs near immune-related GWAS peaks, four hap-ASM
DMRs near GWAS peaks for neurological phenotypes,
and three hap-ASM DMRs in chromosomal regions with
multiple GWAS peaks for both immune- and brain-related
phenotypes. The results confirmed hap-ASM in 12/13 of
these loci (Figures 1, 2, 3, 4, S4, S7, and S10–S17), including
7 chromosomal regions with supra-threshold GWAS
signals of p < 5 3 108 and 5 chromosomal regions
with sub-threshold GWAS signals (p ¼ 9 3 106 to p ¼
1 3 107). Among these examples are candidate suscepti-
bility loci for AD, bipolar disorder (BPAD [MIM: 125480]),
multiple sclerosis, type I diabetes mellitus (IDDM [MIM:
222100]), Crohn disease (IBD1 [MIM: 266600]), immune942 The American Journal of Human Genetics 98, 934–955, May 5, 2016response to a vaccine, and other rele-
vant medical phenotypes. Although
several of these hap-ASM DMRs were
detected in multiple tissues, in our
validations comparing brain and
T cell samples, we found that hap-ASM in the CLECL1 (MIM: 607467) and FRMD1 (MIM:
NA) regions is mostly or entirely T cell specific, whereas
hap-ASM in the MYT1L (MIM: 613084) and CMTM8
(MIM: 607891) regions is mostly or entirely brain specific
(Table 1). In addition, validation of hap-ASM in the
NGFR region in paired neuron and glia from the same indi-
viduals showed strong hap-ASM in neurons and weaker or
absent hap-ASM in glia (Figure S7). Thus, hap-ASM can
provide localizing data and support for the biological
relevance of GWAS signals in a tissue- and cell-type-specific
manner.
Interestingly, for some of the DMRs, hap-ASM was
observed only in a subset of the heterozygous samples
from a given tissue or cell type (Table 1). Such variation
might be explained either by environmental effects on
the epigenetic patterns or by a genetic mechanism in
which the combined effect of several SNPs in a haplotype
block, not just the index SNP, could dictate the presence
or absence of hap-ASM. To test the latter possibility, we
focused on the FRMD1 region, which showed hap-ASM
in about half of the heterozygous T cell samples. We geno-
typed 10 heterozygous individuals using a 600 bp ampli-
con centered on the index SNP, with cloning and Sanger
sequencing of the clones. Based on the resulting phased
haplotypes, we found that 5/5 of the samples with hap-
ASM shared the same extended haplotype including
Figure 4. Hap-ASM in the Upstream Pro-
moter Region of the Immune Phenotype-
Associated IRF1 Gene
The map and browser tracks show the
two hap-ASM DMRs identified from Agi-
lent Methyl-Seq (black rectangles) in the
region immediately upstream of IRF1.
The 150 kb window centered on the
hap-ASM DMRs contains immune-related
GWAS peaks tagged by SNPs rs12521868
and rs4143832 (GWAS p values 1020 and
1010, respectively). Hap-ASM is consis-
tently observed in T cells and is much
weaker in brain, which confirms the pres-
ence of mQTL only in T cells. Unlike the
hap-ASM in the S100A* cluster, here the
‘‘shoulders’’ around the hap-ASM are
biphasic, lowmethylated and highmethyl-
ated, regions. The DMR is coincident with
a dynamic chromatin region, poised in
embryonic stem cells and active in differ-
entiated cells. Representative samples of
each queried tissue are shown. p values
were calculated as in Figure 1. Abbrevia-
tions are as follows: *, Sanger sequencing;
GM12878, lymphoblastoid cell line,
H1-ESC, human embryonic stem cell,
K562, leukemia cell line, NS, not signifi-
cant; chrom., chromatin states from the
Roadmap Epigenomics project.rs1565441, rs1565442, rs1565443, rs6937877, and
rs9364402 in the heterozygous configuration AAAA/BBBB
(Figure S11). Conversely, none of the samples that were
negative for hap-ASM had this haplotype configuration,
instead having other configurations such as AAAA/AABBB
(Figure S11). To confirm this finding, we carried out addi-
tional bis-seq and genotyping in two pairs of monozygotic
twins heterozygous for the index SNP, in which one pair
showed hap-ASM and the other did not. The pair with
hap-ASM carried the AAAAA/BBBBB haplotype configura-
tion, whereas the pair that was negative for hap-ASM did
not (Figure S11). These results show that extended haplo-
types, rather than single proximal SNPs, dictate the allelic
asymmetry at some hap-ASM DMRs.
To exclude imprinting as an explanation for ASM at any
of these loci, we tested the probability of ASM under the
imprinting hypothesis, namely that methylation of an
allele is determined by the parent of origin, not the local
haplotype. Using genotypes of the index SNPs, the
imprinting hypothesis, which predicts a random, geno-
type-independent pattern of ASM, was rejected (binomial
test p value < 0.05) for 10 of the 12 loci with validated
ASM, and not conclusive for the remaining two DMRs
because of the small number of heterozygotes. This
outcome gives strong confidence that the large majority
of ASM DMRs identified by our genome-wide screen
indeed represent hap-ASM, not genomic imprinting.The American Journal of HumaLastly, because the ‘‘sixth base’’
5-hydroxy-methylcytosine (5hmC) is
abundant in brain and especiallyneurons, we carried out oxy-bis-seq for three brain-associ-
ated hap-ASM DMRs. This procedure showed that both
5mC and 5hmC contribute to hap-ASM, making contribu-
tions to the allelic asymmetry in the same direction
(Figure S18).
DMR Mapping and Bioinformatic Enrichment
Analyses Support Variation in CTCF and TF Binding
Sites as a Mechanism Underlying Hap-ASM and
mQTLs
Fine-Mapping of Hap-ASM Shows Discrete DMRs Overlapping
with Regulatory Sequences
Determining the boundaries of DMRs is crucial for testing
mechanistic hypothesis, but most prior studies have not
defined such boundaries. The examples of hap-ASM that
we mapped previously,14 and the ZFP57 DMR described
above, are all small discrete regions, 1 to 2 kb in size. To
see whether these findings would generalize, we asked
whether our 450K data had sufficient CpG coverage to
define DMR boundaries. Inferring DMR sizes from these
data is limited by the CpG coverage of the Beadchips, so
to overcome this limitation, we analyzed our largest
450K dataset, from the T cells, and focused on the 270
mQTL CpGs in the most CpG-rich, and thus most infor-
mative, regions (134 mQTLs; see Material and Methods).
Putative boundaries of mQTLs were defined as the pres-
ence of at least two consecutive CpGs lacking significantn Genetics 98, 934–955, May 5, 2016 943
correlations with the index SNPs. By this procedure, the
median DMR length was 720 bp, with 90% of DMRs span-
ning less than 2,000 bp (Figure S8). We observed higher
methylation levels in the flanking CpGs for 38% of the
DMRs, with the mQTL region corresponding to a low
methylated well. For 15% of the DMRs, the flanking
CpGs showed lower methylation levels (inverted well),
and for 47% we observed a biphasic pattern, with one
methylated and one unmethylated ‘‘shoulder’’ (Figure S8).
Taking a different approach, we used our Methyl-Seq
data and searched for hap-ASM regions for which the
2,000 bp upstream and downstream flanking regions con-
tained at least one heterozygous SNP in the samples with
hap-ASM. We identified 7 such informative regions, and
for 5 of them the DMR size was less than 2,000 bp
(Figure S9). In addition, we used targeted bis-seq to map
the boundaries of three additional hap-ASM regions from
our genome-wide discovery set. We designed contigs of
bis-seq amplicons upstream and downstream of DMRs in
the S100A* cluster (chr1), PXDN (chr2), and IRF1 (chr5) re-
gions (S100A13 [MIM: 601989], S100A14 [MIM: 607986],
PXDN [MIM: 605158], IRF1 [MIM: 147575]). We required
each amplicon to cover a high-frequency SNP and at least
three CpGs. From the resulting data, the DMRs in all three
regions were discrete, spanning from 1 to 2 kb of DNA and
having well-defined boundaries (Figures 3, 4, and S10).
Like the ZFP57 DMR, the DMR in the S100A* region was
identified in both mQTL and Methyl-Seq discovery sets
and precisely coincides with a CTCF ChIP-seq peak. More-
over, in this DMR the index SNP is in a CTCF binding site
sequence motif (Figure 3). As indicated by ENCODE data,
the PXDN-MYTL DMR coincides with polymorphic MYC
TF and CTCF binding motifs. Both motifs are associated
with cell-type-restricted ChIP-seq peaks, which can
explain the cell-type-specific hap-ASM at this locus
(Figure S10). Although the IRF1-IL5 (MIM: 147850) hap-
ASM DMRs and mQTL did not overlap a CTCF site or
known TF binding site, they were located in a region of
poised chromatin (Figure 4). These examples highlight ge-
netic variations in DNA regulatory elements as a potential
mechanism for some, though perhaps not all, examples of
hap-ASM, a hypothesis that we test globally below.
Hap-ASM DMRs and mQTLs Are Enriched in Specific Chromatin
States
The Epigenomics Roadmap consortium identified 15 chro-
matin states that show different average levels of DNA
methylation, different degrees of evolutionary conserva-
tion, and differences in several other features.35 For
example, states associated with bivalent enhancers show
a broad distribution of methylation levels, standard het-
erochromatin and heterochromatin associated with ZNF
genes and repeats (here we use the standard ENCODE
term for this class of sequences) are depleted for evolution-
arily conserved elements, and so on. Each of the 15 chro-
matin states are enriched in specific histone marks:
repressed Polycomb state in H3K27me3; bivalent enhancer
chromatin in H3K27me3 and H3K4me1; heterochromatin944 The American Journal of Human Genetics 98, 934–955, May 5, 2in H3K9me3, and heterochromatin associated with ZNF
genes and repeats in H3K36me3 and H3K9me3.35 As
shown in Figure S19, among both hap-ASM DMRs and
mQTLs combined across tissues, we found significant
enrichments in repressed Polycomb state, bivalent en-
hancers, enhancers, heterochromatin, and heterochro-
matin associated with ZNF genes and repeats. Conversely,
significant under-representation was found for regions
classified as active TSS state. Our analysis of the mQTL
data showed an enrichment of PRC2-bound regions and
enhancers, as well as an under-representation in active
promoters in every queried cell and tissue, whereas enrich-
ments of the other chromatin states were more tissue
dependent (Figure S20). Given that polycomb-bound and
bivalent enhancers are associated with developmentally
regulated genes36 and that polycomb-repressed states, en-
hancers, and heterochromatin are often tissue specific,
whereas active promoters and transcribed states are more
often constitutive,35 these findings indicate that hap-
ASM DMRs and mQTLs occur preferentially in develop-
mentally regulated chromatin states and are relatively
depleted in regions of constitutive chromatin.
Hap-ASM DMRs and mQTLs Are Enriched in Polymorphic and
Tissue-Specific CTCF Binding Sites
Insulator sequences occupied by CTCF are a unique chro-
matin state that regulates promoter-enhancer interactions
via chromatin looping. Because our previously published
findings,14 as well as recently published data from lympho-
blastoid cell lines,37 and the additional examples of hap-
ASM loci described above implicate CTCF binding sites in
hap-ASM, we next tested our hap-ASM and mQTL datasets
overall for statistical enrichment in CTCF ChIP-seq peaks
and polymorphic CTCF binding motifs. We defined strong
peaks as the top 25th percentile in ENCODE ChIP-seq data.
The results showed that hap-ASM DMRs are enriched in
strong CTCF peaks that are present in one or multiple
cell types (OR ¼ 2.2, p ¼ 0.001), but not in strong
CTCF peaks identified in almost all (>75%) of the assessed
cell types (Figure 5A). Similar results were obtained for
our mQTL dataset, with a stronger enrichment in cell-
type-restricted CTCF peaks than in pan-cell type CTCF
peaks (OR ¼ 3.3, p ¼ 1.8 3 1029 and OR ¼ 1.5, p ¼
3.4 3 1007, respectively) (Figure 5A). In contrast, weak
CTCF peaks were not enriched in either of our datasets.
In our next level of testing, we focused on CTCF binding
motifs. Because the number of canonical binding motif oc-
currences in the human genome is lower than the total
number of CTCF ChIP-seq peaks, to increase the number
of evaluable loci we combined ChIP-seq data from any tis-
sue or cell type and included both the canonical motifs and
the de novo predicted CTCF binding motifs identified by
Kheradpour et al.23 By this strategy we identified 4,164
informative regions, including 51 hap-ASM DMRs, over-
lapping with CTCF binding motif occurrences. We defined
informative motifs as those overlapping an index SNP and
divided these into three classes: (A) polymorphic motifs
with or without a CpG, (B) CpG-containing invariant016
Figure 5. Hap-ASM DMRs and mQTLs
Coincide with Low-Methylated Wells and
Are Enriched in Polymorphic CTCF Bind-
ing Sites
(A) The graphs show a strong overall
enrichment in polymorphic CTCF motifs
among both hap-ASM regions andmQTLs.
CTCF motifs were categorized into three
classes: invariant CTCF motifs without
CpG (considered as reference class),
invariant CTCF motifs with CpG, and
polymorphic CTCF motifs. Enrichment is
expressed by the odds ratio (OR) on the
y axis.
(B) Bar graph showing increasing enrich-
ment of polymorphic CTCF motifs with
the number of ASM CpGs in the DMR. To
avoid potential bias due to different CpG
density between the hap-ASM DMRs and
the background, ORs are adjusted for the
number of CpGs covered by at least 10
reads per allele. A positive correlation is
observed between OR and the number
(i.e., local density) of CpGs with ASM.
(C) The graph shows the averaged net
methylation of all CpGs within51,000 bp
of the center of all hap-ASM DMRs that
overlap polymorphic CTCF motifs. This
result indicates that hap-ASM DMRs asso-
ciated with CTCF sites are discrete and
occur in low methylated ‘‘wells.’’ Values
are binned by 100 bp (dots) and Lowess
smoothing performed (curve). The map
and net methylation data show, as an
example, the hap-ASM region associated
with SNP rs9330298 in the S100A* gene
cluster. The hap-ASM overlaps a polymor-
phic CTCF site; in the homozygous AA
sample, this is a low-methylated region,
reflecting CTCF binding, surrounded by
hypermethylated ‘‘shoulders.’’ A, reference
allele; B, alternate allele.motifs, and (C) invariant motifs without a CpG. We ex-
pected class C motifs to have the least association with
ASM, and we therefore used them as a reference in logistic
regression. As shown in Figure 5B, hap-ASM DMRs indeed
proved to be enriched only in polymorphic CTCF motifs
(OR ¼ 3.1; p ¼ 3.5 3 1005). We next grouped the hap-
ASM regions into three categories with increasing ASM
CpG-content (3–4, 4–5, and R6 ASM CpGs). Logistic
regression was adjusted for the number of CpGs with
good coverage so that CpG-rich hap-ASM regions are not
compared to CpG poor background. As shown in
Figure 5B, we found that enrichment in polymorphic
CTCF motifs increases with the number of hap-ASM
CpGs in the DMR. Similarly, mQTLs were strongly en-
riched in polymorphic CTCF motifs (OR ¼ 7.8; p ¼
2.23 1069) (Figure 5B). The results were robust in each tis-
sue type (Figure S21) and were stable when using larger
500 bp windows around each index SNP. These findings
of strong enrichment in polymorphic but not invariant
CTCF motifs, with a strong hap-ASM CpG density effect,
supports allele-specific binding of CTCF as a sequence-The Amdependent mechanism underlying a subset of hap-ASM
loci. We then analyzed the averaged net methylation of
all CpGs within 51,000 bp of the center of hap-ASM
DMRs that overlap polymorphic CTCF motifs (200 bp
window). We found that these hap-ASM DMRs were coin-
cident with low methylated ‘‘wells,’’ which is consistent
with selective CTCF binding to the unmethylated alleles
(Figures 5C and S21).
Lastly, to ask whether hap-ASM regions with polymor-
phic CTCF binding sites in fact exhibit allele-specific bind-
ing of CTCF, we used available whole-genome sequencing
(1000 Genomes project; SRA: SRA029810, SRA175417,
SRA062045) and ChIP-seq data (ENCODE; GEO:
GSM733752) in the GM12878 lymphoblastoid cell line.
Among our hap-ASM DMRs with polymorphic CTCF mo-
tifs, two loci were informative (heterozygous SNP genotype
and coverageR 103) in the GM12878 cells. We performed
Sanger bis-seq on GM12878 cell DNA and indeed found
hap-ASM at these loci (Figure S22). In other words,
although WGS data contained DNA fragments mapping
to both alleles for rs9330298 and rs12975442 in this cellerican Journal of Human Genetics 98, 934–955, May 5, 2016 945
line, the ChIP-seq data revealed allele-specific binding of
CTCF, withmost of the CTCF-boundDNA fragments align-
ing to the unmethylated alleles (p ¼ 1.2 3 1011 and p ¼
1.9 3 1007, respectively, allelic bias tested by binomial
test), and with a weaker ChIP-seq asymmetry underlying
the weaker but significant hap-ASM for rs12975442
(Figure S22).
Hap-ASM DMRs and mQTLs Are Enriched in Polymorphic
Binding Sites for a Group of TFs
Allele-specific TF binding occurs at up to 5% of genomic
sites,38 and TF occupancy might play a role in shaping
DNA methylation patterns.39 We therefore asked whether
hap-ASM loci might also be enriched in polymorphic TF
binding sites other than CTCF. We overlapped our data
to all TF canonical motif occurrences in ENCODE data
and found 9,409 informative occurrences. Similar to our
strategy for CTCF, we grouped these TF motifs into three
classes: (A) polymorphic, (B) invariant with CpG sites,
and (C) invariant without CpG. From our Methyl-Seq
data, we found 19 TFs, including MYC and MEF2, with
an enrichment OR R 1.5 among hap-ASM loci
(Figure S23 and Table S11). Overall, hap-ASM was strongly
and significantly enriched in polymorphic motifs of at
least one of these TFs (OR ¼ 2.9, p ¼ 4.9 3 107). Support-
ing a role for allele-specific binding of TFs in hap-ASM, four
of these factors—MYC, AP1, CEBPB, and GATA1—can
show methylation-sensitive binding.40–44 In our mQTL
data, among informative TF motif occurrences, we identi-
fied 34 polymorphic TF motifs with an OR > 1.5 in
T cells, 34 in placenta, and 30 in brain TC (Figure S23
and Table S11). Some of these TFs, such as AP1, CREB,
YY1, ZNF143, and ZNF263, are found in each tissue, but
others are more tissue specific. Overall, as shown in
Figure S23, we found strong enrichment of the polymor-
phic motifs of at least one of these TFs among mQTLs in
each tissue (OR ¼ 5.1, p ¼ 8.3 3 1056 in T cells, OR ¼
4.9, p ¼ 7.1 3 1040 in placenta, and OR ¼ 3.8, p ¼
1.1 3 1018 in brain TC). These results were also found
in neurons and glia (Figure S23) and were robust when us-
ing the 500 bp window size. Next, the analysis of net
methylation of the flanking regions of hap-ASM DMRs
that overlap polymorphic TFs motifs (200 bp window)
showed, once again, that that these hap-ASM DMRs were
coincident with low methylated ‘‘wells,’’ although more
heterogeneity is observed compared to CTCF (Figure S24).
To further test allele-specific CTCF and TF binding as a
mechanism for hap-ASM, we estimated the binding likeli-
hood to each allele at polymorphic CTCF and TF motif oc-
currences within 200 bp windows of hap-ASM DMRs,
based on probability weight matrices from ENCODE. As
shown in Figure 6, for CTCF, the difference of PWM score
between alleles was significantly anti-correlated with the
difference of methylation, suggesting that lack of CTCF oc-
cupancy is mostly associated with hypermethylation and
that SNPs with higher disruptive effects are associated
with stronger hap-ASM. For TF polymorphic motif occur-
rences, we identified two sets of TFs, one set for which rela-946 The American Journal of Human Genetics 98, 934–955, May 5, 2tive hypermethylation was associated with low binding
likelihood, suggesting protection against methylation,
and a set where hypermethylation was associated with
high binding likelihood, suggesting gains of methylation
mediated by TF occupancy (Figure 6).
Cross-species Comparisons of Methylation Patterns Validate the
CTCF Hypothesis and Point to Variation in CTCF Binding Sites as
a Mechanism for Gains and Losses of Hap-ASM in Evolution
As noted above, hap-ASM DMRs are relatively enriched in
non-conserved sequence elements. Capitalizing on this
observation, as an additional test of the CTCF hypothesis,
we used a cross-species approach in which we carried out
targeted bis-seq in PBL and liver from macaque monkeys
at five loci orthologous to human loci with CTCF motifs.
We chose these loci such that the macaque sequences
diverged from human sequences at critical base pairs in
these motifs. As shown in Figures 7, S25, and S26, the re-
sults at each of the five DMRs confirmed the expected
negative correlation between the methylation levels (as
determined by bis-seq) and CTCF binding likelihood (as
indicated by the PWM score) when comparing each hu-
man allele and the monkey alleles.
Chromosomal Regions around Hap-ASM DMRs and
mQTLs Are Enriched in eQTLs
Post-GWAS mapping strategies based on hap-ASM DMRs,
mQTLs, and eQTLs each have technical advantages and
disadvantages, making a combined approach desirable.17
Thus, although the current study is focused on methyl-
ation, we were interested in overlaps of our data with
eQTLs. Based on the eQTL browser, 9% of the hap-ASM re-
gions and 50% of themQTLs in the datasets described here
lie in 150 kb windows that also contain at least one eQTL
(the higher yield of mQTL-eQTL pairs probably reflecting
the gene-centered design of the 450K methylation arrays,
as compared to the more distributed genomic coverage of
Agilent SureSelect Methyl-Seq). Among these parings are
ZFP57, CLECL1, HLA-DRB* (HLA-DRB1 [MIM: 142857],
HLA-DRB6 [MIM: NA]), S100A*, and CCDC155 (MIM ¼
NA). Moreover, using all informative genomic regions as
background, we find that both hap-ASMDMRs andmQTLs
are statistically enriched in eQTLs within 20 kb windows
(OR ¼ 1.4, p ¼ 0.008; OR ¼ 1.6, p ¼ 1017, respectively).
For mQTLs, the enrichment was higher for eQTLs within
1,000 bp (OR ¼ 2, p ¼ 4.9 3 1021) and decreased for
more distant eQTLs (OR ¼ 1.2, p ¼ 3.4 3 109 for eQTLs
within 150 kb). Similar results were observed in each tis-
sue. Likewise, the enrichment in eQTLs among hap-ASM
regions was no longer significant overall after a distance
of 40 kb. Thus, hap-ASMmapping can be a useful approach
for identifying candidate genes affected by disease-associ-
ated genetic polymorphisms, especially when multiple
distant SNPs, in linkage disequilibrium, are identified as
GWAS signals. Importantly, enrichment analysis does not
exclude specific instances in which the gene being regu-
lated lies at a greater distance, such as when the key regu-
latory element is an insulator or enhancer, so to avoid016
Figure 6. Methylation Differences be-
tween Alleles at Hap-ASM Loci Correlate
with CTCF and TF Binding Likelihoods
(A) The graph shows methylation differ-
ences between alleles as a function of
CTCF binding likelihood difference, esti-
mated by PWM (position weight matrix)
scores, and averaged across all hap-ASM re-
gions within 5100 bp of a polymorphic
CTCFmotif occurrence. A significant nega-
tive correlation between methylation
difference and CTCF binding likelihood is
observed.
(B) CTCF acts as insulator and barrier
element by blocking the spread of hetero-
chromatin and CpG methylation. Genetic
polymorphism in CTCF binding sites allow
hypermethylation on the allele with lower
or absent occupancy.
(C) The graph shows methylation differ-
ences between alleles as a function of TF
binding likelihood difference, estimated
by PWM scores, and averaged across all
hap-ASM regions within 5100 bp of a
polymorphic TF motif occurrences. Two
subsets of TFs are observed: one with a sig-
nificant negative correlation between
methylation difference and TF binding
likelihood difference (black circle) and
one with a significant positive correlation
(white circle).
(D) These results can be explained by
postulating one class of TFs for which
binding site occupancy is associated
with demethylation of DNA and another
class of TFs where binding is associated
with gains of methylation. For these two
classes of TF, disruption of their binding
motifs by sequence polymorphisms is
therefore associated with allele-specific
DNA hypermethylation or hypomethyla-
tion, respectively.missing such instances we used relatively large 150 kb win-
dows here for tabulating and analyzing hap-ASM DMRs
and mQTLs that map near GWAS peaks.Discussion
These results have basic implications for understanding
mechanisms of genetic-epigenetic interactions and prac-
tical value for validating GWAS peaks and homing in on
causal variants. First considering the latter, identifying
causal SNPs is essential for understanding disease patho-
genesis but statistical associations by themselves cannot
localize these sequences. Also, due to the small effect sizes
of most risk alleles and the stringent significance thresh-
olds necessitated by multiple testing in GWASs, many
true-positive associations, including causal ones, can
show sub-threshold (>5 3 108) p values. As we have pro-
posed,3,16,17 a strategy of overlapping hap-ASM/mQTL
data with GWAS data can help to overcome these road-
blocks. A number of recent studies have started to apply
this promising approach,3,4,6–15 but datasets analyzing dis-The Amease-relevant primary human tissues, applying stringent
criteria for hap-ASM and mQTLs, and using independent
methods for validating the genome-wide profiling and
defining the boundaries of DMRs are still sparse.
Here we have presented genome-wide maps of hap-ASM
and mQTLs, focusing mainly on T lymphocytes and cere-
bral cortical brain tissue, including FANS-isolated neurons
and glia, as well as a smaller set of term placentas. Key tech-
nical aspects of our study include (1) cell-type-specific
profiling of both hap-ASM and mQTLs, leading to an
increased net yield of disease-associated loci, (2) deep
long-read Nextgen sequencing to maximize the yield of
bona fide hap-ASM DMRs, (3) a definition of mQTLs based
not only on p values but also on correlation coefficients
and strength of the methylation asymmetry, and (4) inde-
pendent validations of a diverse subset of the implicated
regions by targeted bisulfite sequencing—with the high
validation rate supporting the accuracy of our genome-
wide datasets. The importance of defining mQTLs based
not only on p values but also on correlation coefficients
and strength of the methylation asymmetry is highlighted
by our bis-seq data in Figure S27, which show that someerican Journal of Human Genetics 98, 934–955, May 5, 2016 947
Figure 7. Comparison of Human and
Macaque Methylation Patterns Supports
the Correlation between Allele-Specific
CTCF Binding Likelihood and Hap-ASM
(A)Map and graphs of netmethylation in a
30 kb window containing a hap-ASMDMR
encompassing SNP rs117902864. This SNP
is relatively uncommon (minor allele fre-
quency ¼ 3%) and its detection in the
only heterozygous T cell sample confirms
the usefulness of the Methyl-Seq approach
to identify rare hap-ASM DMRs. The hap-
ASM overlaps a polymorphic CTCF bind-
ing site, in which the rare allele reduces
binding likelihood (PWM score). Net me-
thylation in homozygous samples showed
that the DMR is located in a low-methyl-
ated region surrounded by high-methyl-
ated shoulders. The single heterozygous
sample shows hypermethylation, consis-
tent with a role for CTCF binding in main-
taining the low-methylation level. GWAS
significance levels are: rs6558578, HPV cer-
vical cancer, p¼ 7.003 1006; rs13263558,
weight/body mass/obesity-related (obesity
[MIM: 601665]) traits, p ¼ 3.00 3 1006;
rs2235121, bipolar disorder and schizo-
phrenia, p ¼ 8.00 3 1006.
(B) The sequence of the CTCF motif is
shown for each human allele and for
Macaca mulatta. The methylated allele
(allele B) is associated with lower PWM
score than allele A. No SNP is present in
the CTCFmotif instance inMacaca mulatta
(rectangle). The macaque sequence differs from the human reference allele by one nucleotide (bold and underlined nucleotide), but this
change does not alter CTCF binding likelihood. Sanger bis-seq of this region in PBL from two monkeys shows low methylation levels,
similar to the methylation level observed in allele A in human T cells. Methylation data were obtained by MiSEQ for human and Sanger
sequencing for macaque. Additional hap-ASM loci analyzed by this type of cross-species comparison are in Figures S25 and S26. Abbre-
viations are as follows: PWM, position weight matrix; A, reference allele; B, alternate allele.candidate mQTLs from a prior study15 that relied solely on
statistical significance and therefore harvested a very large
number of candidates (>10,000) are actually false posi-
tives. Nonetheless, our data validate a substantial group
of loci from that study. Most importantly, our review of
the prior studies8,10,12,13,15 shows that more than half of
the hap-ASM loci andmQTLs that we report here are newly
discovered regions. Hap-ASMmapping requires both infor-
mative SNPs and CpGs, and we have shown that using our
two complementary approaches increases the yield of
identified regions. This seems to be true for other methods
as well: using methyl-sensitive SNP array analysis (MSNP),
we previously identified and fine mapped the DMRs for
two novel examples of imprinted ASM and four hap-ASM
loci.3,14 Of these, the imprinted region in VTRNA2-1 was
informative in our Agilent Methyl-Seq data and the hap-
ASM region in CYP2A7 was queried here by the 450K Illu-
mina methylation Beadchips, with these loci confirmed as
ASM and mQTL, respectively. Likewise, Hutchinson et al.
used MSNP to identify four hap-ASM loci.7 None of them
were informatively queried in our Methyl-Seq data and
only one weak hap-ASM region (rs713875, difference be-
tween allele ¼ 0.03) was queried by our methylation array
data, which showed a subthreshold mQTL (difference be-948 The American Journal of Human Genetics 98, 934–955, May 5, 2tween allele ¼ 0.1, R2 ¼ 0.4, q value ¼ 6 3 1005). In the
future, deep whole-genome bisulfite sequencing with
long reads is expected to add further information.Supra- and Sub-threshold GWAS Peaks for which
mQTL and Hap-ASM Mapping Supports Biological
Relevance
Regarding the loci in which our findings help to promote
GWAS signals to biological true positives, the gene lists
are in Tables S4 and S6–S10 and examples are in Table 1.
Methyl-Seq, but not the mQTL approach, can score hap-
ASM in single heterozygous samples and thereby identify
hap-ASM regions associated with rare SNPs. An interesting
example is provided by the hap-ASM DMR that we de-
tected between KBTBD11 (MIM: NA) and MYOM2 (MIM:
603509) on chromosome 8, for which we show maps
and Methyl-Seq data in Figure 7. This DMR has strong
hap-ASM in T cells and is situated close to a sub-threshold
GWAS signal (p ¼ 7.0 3 106) for susceptibility or resis-
tance to HPV-associated cervical cancers (cervical cancer
[MIM: 603956]).45 The index SNP is rare (~1%MAF), which
explains why this potentially important locus was detected
in our hap-ASM data, but not in our screen for mQTLs.016
Considering the other loci linked to immunological
traits, multiple SNPs near the DMR tagged by SNP
rs12304510 on chromosome 12 are associated with multi-
ple sclerosis and type I diabetes.46–48 Supporting the bio-
logical relevance of this DMR, the genes in this window,
CLECL1, CD69 (MIM: 107273), and CLEC2D (MIM:
605659), are expressed in hematopoietic cells and involved
in T cell function.49–51 Likewise, IRF1 encodes a transcrip-
tion factor that induces type I interferon and IL-27 produc-
tion and is involved in Th17 cell differentiation, which
play a critical role in autoimmune inflammation and viral
infection.52,53 The IRF1-linked hap-ASM DMR, which
is stronger and more consistent in T cells than in brain (Ta-
ble 1 and Figure 4), is located within 75 kb of GWAS SNPs
associated with Crohn disease and asthma (asthma, bron-
chial [MIM: 600807]).54–58 Also relevant to an important
immunological phenotype, a GWAS SNP (rs1473500)
located ~15 kb from the T-cell-specific hap-ASM DMR
that we identified next to FRMD1 on chromosome 6 was
associated with secreted IL-2 in response to smallpox
vaccine.59 Here our supportive epigenetic data are particu-
larly useful, because the GWAS signal was sub-threshold
(3 3 107). Another example is the S100A* gene cluster
and its associated hap-ASM DMR, which is also close to
ILF2 (MIM: 603181), encoding a subunit of nuclear
factor of activated T cells (NFAT) that regulates IL-2 ex-
pression.60 There is a sub-threshold GWAS signal (p ¼
4.0 3 1006) for susceptibility to multiple myeloma
(MIM: 254500) in this region, and our identification of a
strong hap-ASM DMR within 50 kb of the GWAS peak
helps to nominate this signal to a biological true positive,
as well as raising the possibility of a role for S100A* or
ILF2 in immune surveillance against multiple myeloma.
Another group of hap-ASM DMRs is relevant to both
immunological and neurological phenotypes. The HLA-
DR* genes encode class II histocompatibility molecules
expressed by antigen-presenting cells, and genetic variants
in these genes are associated with autoimmune disor-
ders.48,61,62 However, there have also been reports of
genetic associations of HLA-DR genes with neurological
disorders including schizophrenia63 and AD64 and there is
evidence suggesting a role for histocompatibility antigens
in neuronal connectivity and synaptic plasticity.65,66
A challenge in interpreting statistical associations in the
HLA region is the LD structure, which makes it difficult to
conclude that a disease-associated SNP is causal and not
simply associated with a causal SNP several kb away. As
shown in Figures 2 and S15, we have identified a hap-ASM
DMR in HLA-DRB6, which remarkably is quite strong in
brain samples while showing much weaker and less
frequent allelic asymmetry in T cells. Thus, our hap-ASM
data point to the CTCF-bound insulator element in the
HLA-DRB6 as a candidate for the causal regulatory element
underlying the AD associations64 in this genomic region.
A recent study of 447 AD-affected brains and 293 control
brains using 450K methylation arrays found that net DNA
methylation inHLA-DR* genes is associatedwith late-onsetThe AmAD, with a statistical significance for the global association
at the locus level, butwith associationsnotpassingmultiple
testing correction at the individual CpG level.32 Based on
our data, we propose that this result does not reflect altered
DNAmethylation due to pathological changes in AD brain
tissue, but rather is an indication of HLA-DR* as a suscepti-
bility locus for this disease. Because of the hap-ASM in this
region, this genetic susceptibility will manifest as small
methylationdifferences between cases and controls in large
450K array-based methylation studies. In fact, one of the
AD EWAS-associated CpGs in this region (Illumina ID
cg13972202) was identified as an mQTL in our dataset (Ta-
ble S12), and theother one is a SNP.Another gene associated
withADsusceptibilitywhereweobservedhap-ASM inbrain
is CELF2 (MIM: 602538) (Figure S17). GWAS associations
between SNPs in this gene and late-onset ADwere reported
in APOE ε4 (MIM: 107741) homozygotes, and in vivo data
from mice suggest that CELF2/CUGBP2, an RNA-binding
protein, is involved in apoptosis in hippocampal neu-
rons.67–69
Another example in this group of loci is the hap-ASM
DMR upstream of NGFR on chromosome 17. This gene co-
des for the nerve growth factor receptor, which binds NGF
and promotes neuronal survival, but this receptor is also
expressed in T lymphocytes, for which NGF is mito-
genic.70 As shown in Figure S7, SNPs very close to the
NGFR-linked hap-ASM DMR show near-threshold
statistical associations not only with bipolar disorder, a
brain-related phenotype, but also with a T-cell-related
phenotype, the immune response to smallpox vac-
cine.59,71 With regard to the other hap-ASM DMRs near
GWAS peaks for neurological disorders, CMTM8 is one
of several chemokine-like factor genes located in a cluster
on chromosome 3. This gene is expressed in brain, but its
biological role is not yet known. The CMTM8 hap-ASM
DMR coincides with an intra-genic regulatory region
marked by PRC2 occupancy in brain cells but not in
T cells, and the strength of the allelic asymmetry is stron-
ger in brain (Figure S13). GWAS SNPs associated with bi-
polar disorder and alcohol dependence (MIM: 103780),
both sub-threshold, are within 15 kb of this DMR
(Figure S13), so the epigenetic data help to promote this
locus to a biological true positive. Likewise, MYT1L,
Myelin Transcription Factor 1-Like, codes for a neural-spe-
cific TF expressed in fetal and adult brain. Deletions in
chromosome band 2p25.3 suggest a role of this gene in
intellectual disability72 and a GWAS SNP in MYT1L has
been associated, at near-threshold significance, with
response to antipsychotic treatment.73 The hap-ASM
DMR in this gene overlaps with polymorphic MYC and
CTCF motifs and is located 65 kb from this GWAS signal
(Figure S10). A fourth interesting example, albeit with
weaker and less frequent hap-ASM, is PTPRN2 (MIM:
601698), which has been provisionally associated with bi-
polar disorder, schizophrenia (SCZD [MIM: 181500]),
cocaine dependence, and depression (MDD [MIM:
608516])74,75 (Figure S14).erican Journal of Human Genetics 98, 934–955, May 5, 2016 949
Lastly, published GWASs for placenta-related traits such
as intrauterine growth restriction, preeclampsia (PEE1
[MIM: 189800]), and premature birth are sparse to date
and, probably for this reason, we did not find GWAS/
mQTL overlaps for these conditions. Placentas are rela-
tively under-represented in our current series, so antici-
pating such future GWASs, we are now collaborating
with other investigators to expand the placenta data.
Special Implications of Hap-ASM in ZFP57
Relevant both to disease associations and more generally
to epigenetic gene regulation, the strong hap-ASM DMR
that we identified in ZFP57 is of particular interest.
ZFP57 is located on chromosome 6 in the HLA region
and encodes a TF that acts in trans to regulate genomic
imprinting.26,27 ZFP57 recruits DNMT1 and DNMT3a
through its interaction with KAP1/TRIM28 and is thus
required for acquisition and/or maintenance of a subset
of DNA methylation imprints.76 Loss of imprinting in
several syndromes, particularly transient neonatal diabetes
mellitus type 1, can be associated with mutations in
ZFP57.77,78 In addition, since a knockout of this gene in
mice led to defects in cardiac development,79 our finding
of hap-ASM upstream of this gene suggests that it might
be fruitful to test for associations of ZFP57 haplotypes
with human congenital heart defects (HDCA [MIM:
600001]). More broadly, our findings raise the possibility
that some associations of non-coding SNPs in the HLA
region with complex phenotypes might reflect not only
altered expression of histocompatibility antigens, but
also haplotype-dependent expression of ZFP57, mediated
by or stabilized by hap-ASM, and possibly resulting in
altered expression of imprinted genes.
Mechanisms of Hap-ASM: CTCF Sites, TF Sites, and
Chromatin States
For several loci we carried out fine-mapping to define the
boundaries of hap-ASM DMRs, a step that is crucial for
testing mechanistic hypotheses. Overall, the results high-
light a role for genetic variation in CTCF and TF binding
sites as a mechanism underlying hap-ASM and mQTLs.
Insulators act to establish chromatin loops, which can
separate enhancers from promoters and block the spread
of heterochromatin.80 CTCF is a zinc-finger protein that
is a key component of the insulator complex that anchors
these loops.81 At some imprinted loci, CTCF binding to
DMRs is DNA methylation sensitive, thereby enforcing
allele-specific expression of the imprinted genes,82 and
CTCF binding is also implicated in the formation or main-
tenance of low methylated regions.83 We previously docu-
mented several examples of genes with hap-ASM in which
the differentially methylated regions (DMRs) are discrete
in size (~2 kb) and precisely overlap with binding sites
for CTCF,14 and we proposed a mechanism in which
sequence polymorphisms in CTCF binding sites reduce
or abrogate CTCF binding in a haplotype-dependent
manner and lead to preferential CpG methylation on the950 The American Journal of Human Genetics 98, 934–955, May 5, 2unoccupied or less occupied allele.14,17 Our bioinformatic
analyses presented here, showing enrichment for polymor-
phic CTCF binding sites in hap-ASM/mQTL regions, and
our cross-species comparisons strongly support this model.
In addition, we found an overall enrichment for CTCF
ChIP-seq peaks overlapping with hap-ASM DMRs, some
of them without known or polymorphic motif instances.
For one of these hap-ASM regions, FRMD1, we have shown
that a combination of SNPs, all encompassed in a 450 bp
segment of DNA, together determine the presence or
absence of ASM. So, the simplest mechanistic possibility,
which can be tested in future work, is that binding of
CTCF-associated accessory factors might be influenced by
these sequence variants, thus leading to allele-specific
CTCF site occupancy and thereby allele-specific protection
from CpGmethylation, even though the CTCF site itself is
not polymorphic. In addition to our model in which
altered CTCF binding leads to hap-ASM, in principle at
some loci hap-ASM could ‘‘come first,’’ followed by allele-
specific CTCF binding. We did not find enrichment in
invariant CpG-containing CTCF binding sites among
hap-ASM loci, but we did find examples of such loci. There-
fore, it might be interesting to ask, in future studies,
whether hap-ASM at invariant CpG-containing CTCF
binding sites can be a primary cause of allele-specific bind-
ing of CTCF.
The polymorphic binding site model can also be made
more general: allele-specific transcription factor (TF) bind-
ing can occur in up to 5% of the human genome,38,84
changes in TF binding site occupancy can be responsible
for active or passive demethylation of DNA,39,83 and, for
special TFs such as Pu.1, can mediate gains of methylation
through interaction with DNMTs.85 That polymorphisms
in TF binding sequences can lead to hap-ASMhas been sug-
gested by a recent study using lymphoblastoid cells lines.37
Taken together, our genome-wide, locus-specific, and
cross-species data support both the CTCF-based and
TF-based mechanisms, both for hap-ASM DMRs and for
mQTLs, and in multiple disease-relevant human tissues
and cell types. These results in turn provide a mecha-
nism-based rationale for the strategy of using maps of
hap-ASM and mQTLs for identifying pathogenic variants
in disease-linked regulatory sequences.
Although polymorphic CTCF binding sites are enriched
among hap-ASM DMRs and mQTLs, Tables S4 and S6–S10
show that they still account for only a minority of such
loci. In this regard, our findings regarding chromatin states
might be relevant. Those analyses point to allele-specific
H3K9 methyltransferase recruitment and PRC2 binding
as possible additional mechanisms. Regarding the H3K9
mark, zinc finger protein genes of the repetitive class
constitute a super family of genes that form large hetero-
chromatin regions targeted by H3K9 methyltransferase,
SUV39H1.86 SUV39H1 binds indirectly to DNA through
the interaction between KRAB domain-containing pro-
teins and KAP1 and recruits DNAmethyltransferase to spe-
cific genomic sequences, inducing long-range repression016
through heterochromatin spread. In addition, one third of
the ZNF proteins contain a KRAB domain and some have
been shown to interact with KAP1, suggesting auto-regula-
tory loops.87 Our TF motif analyses found enrichment in
sites for several ZNF TFs, suggesting the disruption of
KRAB-ZNF binding sites as a potential mechanism for
hap-ASM. Likewise, poised chromatin is associated with
genes regulated by the PRC2 complex, which is implicated
in allele-specific chromatin repression at imprinted loci,
and cross-talk between DNA methylation and the
H3K27me3 histone mark in chromosomal regions bound
by PRC2 has been described.88–90 Although the sequences
that recruit PRC2 in humans have not been identified,
accumulating evidence supports a role for cis-regulatory se-
quences through interactions with recruitment factors,91
and allele-specific binding of such accessory factors could
explain our findings.
Gains and Losses of Hap-ASM in Species Divergence
Although we examined a small set of macaque loci, our
data from comparing CTCF binding site sequences and
CpG methylation patterns in human and macaques sug-
gest an interesting line of future work on the possible
role of hap-ASM in species divergence. In particular, the
fact that CTCF binding likelihood tracks with methylation
levels at non-conserved binding sites in macaques and hu-
mans suggests the possibility that evolution at such loci
could account for differences in epigenetic patterning,
chromatin organization, and phenotypic traits among pri-
mates. In fact, in our genome-wide analysis, only 20% of
the polymorphic CTCF binding sites associated with hap-
ASMwere conserved at the sequence level between human
and macaque, a result that is consistent with the general
under-representation of evolutionarily conserved elements
that we found among hap-ASM loci in humans, similar to
what has also been described for eQTLs.92
Implications of Variable Hap-ASM among Individuals
We identified not only numerous tissue-restricted mQTLs
and hap-ASM DMRs, but also hap-ASM DMRs that are
present in some individuals but not others with the same
genotype at the index SNP. Both in our Methyl-Seq data
(Table S4) and among the loci that we chose for targeted
bis-seq (Table 1), this finding of individual variation of
hap-ASM is the rule rather than the exception. As we
have demonstrated for hap-ASM in the FRMD1 region,
the combined effects of several SNPs in an extended haplo-
type, only partially captured by genotyping the index SNP,
can explain some examples this variability (Figure S11).
However, another possibility is that some haplotypes
might be permissive for hap-ASM in heterozygotes only
under certain environmental conditions. Altered CpG
methylation patterns have been associated with diverse
environmental factors,93 and future large-scale genetic
epidemiological and twin studies might reveal whether in-
dividual-restricted hap-ASM could be capturing some of
these gene-environment interactions.The AmAccession Numbers
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